BSH 2017 | Managing transplant ineligible AML patients
Mhairi Copland
• 29 Mar 2017
Mhairi Copland, PhD, MB, ChB, MRCP, FRCPath from the University of Glasgow, Glasgow, UK, discusses the management of transplant ineligible acute myeloid leukemia (AML) patients at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. These patients tend to be elderly and there are a range of therapies that can be offered depending on their fitness. If they are not suitable for an intensive chemotherapy-based approach, one can look at hypomethylating agents such azacitidine. For frailer patients, there is the option of combining low-dose chemotherapy potentially with small molecules. However, sometimes the best option is supportive care.
